CHEK1 and neutropenia: These agents often carry a higher toxicity burden, usually manageablewith dose adjustments and supportive measures.84 In general, inhibitors ofATR-CHK1-WEE1 are characterized by hematological toxicity, with anemia moreprominent with ATR inhibitors and neutropenia with CHK1 and WEE1 inhibitors.However, safety data are still accumulating.